Evidence map›Paper›PMID 41577954›Full record

ArticleScientific reports2026

Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILD.

Yoshihiro Kitahara, Tomoyuki Fujisawa, Atsuki Fukada, Keigo Koda, Taisuke Akamatsu, Masaki Ikeda, Masato Fujii, Mitsuru Niwa, Yusuke Kaida, Hiroyuki Matsuda and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Yoshihiro KitaharaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0001-9211-3173
Tomoyuki FujisawaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan. fujisawa@hama-med.ac.jp.ORCID http://orcid.org/0000-0002-8809-1781
Atsuki FukadaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Keigo KodaDepartment of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.
Taisuke AkamatsuDepartment of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.ORCID http://orcid.org/0000-0003-3255-6268
Masaki IkedaDepartment of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan.
Masato FujiiDepartment of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
Mitsuru NiwaDepartment of Respiratory Medicine, Hamamatsu Medical Center, Hamamatsu, Japan.
Yusuke KaidaDepartment of Respiratory Medicine, Enshu Hospital, Hamamatsu, Japan.
Hiroyuki MatsudaDepartment of Respiratory Medicine, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
Koshi YokomuraDepartment of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Naoki KoshimizuDepartment of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan.
Mikio ToyoshimaDepartment of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.
Shiro ImokawaDepartment of Respiratory Medicine, Iwata City Hospital, Iwata, Japan.
Dai HashimotoDepartment of Respiratory Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Keita YamashitaDepartment of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID http://orcid.org/0000-0002-0049-0834
Moriya IwaizumiDepartment of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID http://orcid.org/0000-0002-2629-0830
Masato MaekawaDepartment of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID http://orcid.org/0000-0001-9710-5324
Yusuke InoueSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0001-8075-0597
Hideki YasuiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0002-7134-3364
Hironao HozumiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0001-5439-1543
Yuzo SuzukiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0001-6154-9791
Masato KarayamaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0003-0455-4070
Kazuki FuruhashiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0003-4079-5509
Noriyuki EnomotoSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0003-3187-4264
Naoki InuiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0002-4624-7119
Takafumi SudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.ORCID http://orcid.org/0000-0001-5300-0504

Funding

Japan Society for the Promotion of Science 22K08231
6 · The paper itself

Abstract

This study aimed to assess the clinical utility of serum interferon-lambda 3 (IFN-λ3) as a sequential biomarker for treatment response and disease control in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM)-associated interstitial lung disease (ILD). Serum IFN-λ3 levels were measured in 24 patients with anti-MDA5 antibody-positive DM-ILD at diagnosis and 1 month after initiating immunosuppressive therapy. Patients were categorized into two groups based on clinical outcomes: a good control group (n = 16; survived without relapse for ≥ 1 year) and a poor control group (n = 8; died from ILD progression or relapse within 1 year). Changes in serum IFN-λ3 levels and differences between groups were analyzed. In the good control group, serum IFN-λ3 levels significantly decreased from 94.6 to 12.7 pg/mL (p < 0.001), whereas no significant change was observed in the poor control group (129.0 to 118.8 pg/mL). Furthermore, serum IFN-λ3 levels at 1 month were significantly lower in the good control group than in the poor control group (p = 0.004). Serum IFN-λ3 levels may reflect short-term treatment response and could serve as a useful sequential biomarker for assessing disease control in patients with anti-MDA5 antibody-positive DM-ILD.

Indexed as

DermatomyositisInterferon-Induced Helicase, IFIH1InterferonsInterleukinsLung Diseases, InterstitialAgedAutoantibodiesBiomarkersFemaleHumansImmunosuppressive AgentsInterferon LambdaMaleMiddle AgedAutoantibodiesBiomarkersIFIH1 protein, humanImmunosuppressive AgentsInterferon-Induced Helicase, IFIH1Interferon Lambdainterferon-lambda, humanInterferonsInterleukinsDermatomyositisInterferon-lambda 3Interstitial lung diseaseMelanoma differentiation-associated gene 5Polymyositis

Identifiers

PMID41577954
PMCPMC12901154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.